HPV genotype distribution in older Danish women undergoing surgery due to cervical cancer

Anne Hammer, Else Mejlgaard, Patti Gravitt, Estrid Høgdall, Pernille Christiansen, Torben Steiniche, Jan Blaakær

Research output: Contribution to journalArticle

Abstract

Introduction. The prevalence of human papillomavirus (HPV)16/18 in cervical cancer may decrease with age. This study aimed to describe the HPV genotype distribution in Danish women aged 55 years or older with cervical cancer. Material and methods. In this cross-sectional study we identified 153 cases of cervical cancer diagnosed at Aarhus University Hospital, Denmark (1990-2012) and Copenhagen University Hospital Herlev, Denmark (2007-2012). All women had surgery to treat the disease. HPV genotyping was performed on cervical cancer tissue using the INNO LiPA HPV genotyping extra (Fujirebio, Belgium) at the Department of Pathology, Aarhus University Hospital, Denmark. The main outcome was to estimate the age-specific prevalence of high-risk HPV genotypes included in the bivalent, the quadrivalent, and the nonavalent vaccine. Results. Of 121 cases of cervical cancer included in this study, 113 were HPV-positive (93.4%). Although HPV16 and 18 were the most common genotypes overall, the prevalence of HPV16/18 decreased significantly from 78.1% in women aged 55-59 years to 45.5% in women aged 75 or older (p <0.001), whereas the prevalence of other HPV types and HPV-negative cases tended to increase with age (p = 0.1). The prevalence of HPV types included in the nonavalent vaccine was stable around 90% until the age of 75 years and then dropped to 63%. Conclusion. In the absence of waning immunity, the nonavalent HPV vaccine would be predicted to reduce cervical cancer burden in Denmark across a broader age-range compared with the reduced type-spectrum vaccines.

Original languageEnglish (US)
Pages (from-to)1262-1268
Number of pages7
JournalActa Obstetricia et Gynecologica Scandinavica
Volume94
Issue number11
DOIs
StatePublished - Nov 1 2015
Externally publishedYes

Fingerprint

Uterine Cervical Neoplasms
Genotype
Denmark
Vaccines
Papillomavirus Vaccines
Human papillomavirus 18
Human papillomavirus 16
Belgium
Immunity
Cross-Sectional Studies
Pathology

Keywords

  • Cervical cancer
  • genotypes
  • human papillomavirus
  • human papillomavirus vaccine
  • older women

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Medicine(all)

Cite this

Hammer, A., Mejlgaard, E., Gravitt, P., Høgdall, E., Christiansen, P., Steiniche, T., & Blaakær, J. (2015). HPV genotype distribution in older Danish women undergoing surgery due to cervical cancer. Acta Obstetricia et Gynecologica Scandinavica, 94(11), 1262-1268. https://doi.org/10.1111/aogs.12731

HPV genotype distribution in older Danish women undergoing surgery due to cervical cancer. / Hammer, Anne; Mejlgaard, Else; Gravitt, Patti; Høgdall, Estrid; Christiansen, Pernille; Steiniche, Torben; Blaakær, Jan.

In: Acta Obstetricia et Gynecologica Scandinavica, Vol. 94, No. 11, 01.11.2015, p. 1262-1268.

Research output: Contribution to journalArticle

Hammer, A, Mejlgaard, E, Gravitt, P, Høgdall, E, Christiansen, P, Steiniche, T & Blaakær, J 2015, 'HPV genotype distribution in older Danish women undergoing surgery due to cervical cancer', Acta Obstetricia et Gynecologica Scandinavica, vol. 94, no. 11, pp. 1262-1268. https://doi.org/10.1111/aogs.12731
Hammer A, Mejlgaard E, Gravitt P, Høgdall E, Christiansen P, Steiniche T et al. HPV genotype distribution in older Danish women undergoing surgery due to cervical cancer. Acta Obstetricia et Gynecologica Scandinavica. 2015 Nov 1;94(11):1262-1268. https://doi.org/10.1111/aogs.12731
Hammer, Anne ; Mejlgaard, Else ; Gravitt, Patti ; Høgdall, Estrid ; Christiansen, Pernille ; Steiniche, Torben ; Blaakær, Jan. / HPV genotype distribution in older Danish women undergoing surgery due to cervical cancer. In: Acta Obstetricia et Gynecologica Scandinavica. 2015 ; Vol. 94, No. 11. pp. 1262-1268.
@article{7de1c4d75a5e484bb0cefb7aabaa3114,
title = "HPV genotype distribution in older Danish women undergoing surgery due to cervical cancer",
abstract = "Introduction. The prevalence of human papillomavirus (HPV)16/18 in cervical cancer may decrease with age. This study aimed to describe the HPV genotype distribution in Danish women aged 55 years or older with cervical cancer. Material and methods. In this cross-sectional study we identified 153 cases of cervical cancer diagnosed at Aarhus University Hospital, Denmark (1990-2012) and Copenhagen University Hospital Herlev, Denmark (2007-2012). All women had surgery to treat the disease. HPV genotyping was performed on cervical cancer tissue using the INNO LiPA HPV genotyping extra (Fujirebio, Belgium) at the Department of Pathology, Aarhus University Hospital, Denmark. The main outcome was to estimate the age-specific prevalence of high-risk HPV genotypes included in the bivalent, the quadrivalent, and the nonavalent vaccine. Results. Of 121 cases of cervical cancer included in this study, 113 were HPV-positive (93.4{\%}). Although HPV16 and 18 were the most common genotypes overall, the prevalence of HPV16/18 decreased significantly from 78.1{\%} in women aged 55-59 years to 45.5{\%} in women aged 75 or older (p <0.001), whereas the prevalence of other HPV types and HPV-negative cases tended to increase with age (p = 0.1). The prevalence of HPV types included in the nonavalent vaccine was stable around 90{\%} until the age of 75 years and then dropped to 63{\%}. Conclusion. In the absence of waning immunity, the nonavalent HPV vaccine would be predicted to reduce cervical cancer burden in Denmark across a broader age-range compared with the reduced type-spectrum vaccines.",
keywords = "Cervical cancer, genotypes, human papillomavirus, human papillomavirus vaccine, older women",
author = "Anne Hammer and Else Mejlgaard and Patti Gravitt and Estrid H{\o}gdall and Pernille Christiansen and Torben Steiniche and Jan Blaak{\ae}r",
year = "2015",
month = "11",
day = "1",
doi = "10.1111/aogs.12731",
language = "English (US)",
volume = "94",
pages = "1262--1268",
journal = "Acta Obstetricia et Gynecologica Scandinavica",
issn = "0001-6349",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - HPV genotype distribution in older Danish women undergoing surgery due to cervical cancer

AU - Hammer, Anne

AU - Mejlgaard, Else

AU - Gravitt, Patti

AU - Høgdall, Estrid

AU - Christiansen, Pernille

AU - Steiniche, Torben

AU - Blaakær, Jan

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Introduction. The prevalence of human papillomavirus (HPV)16/18 in cervical cancer may decrease with age. This study aimed to describe the HPV genotype distribution in Danish women aged 55 years or older with cervical cancer. Material and methods. In this cross-sectional study we identified 153 cases of cervical cancer diagnosed at Aarhus University Hospital, Denmark (1990-2012) and Copenhagen University Hospital Herlev, Denmark (2007-2012). All women had surgery to treat the disease. HPV genotyping was performed on cervical cancer tissue using the INNO LiPA HPV genotyping extra (Fujirebio, Belgium) at the Department of Pathology, Aarhus University Hospital, Denmark. The main outcome was to estimate the age-specific prevalence of high-risk HPV genotypes included in the bivalent, the quadrivalent, and the nonavalent vaccine. Results. Of 121 cases of cervical cancer included in this study, 113 were HPV-positive (93.4%). Although HPV16 and 18 were the most common genotypes overall, the prevalence of HPV16/18 decreased significantly from 78.1% in women aged 55-59 years to 45.5% in women aged 75 or older (p <0.001), whereas the prevalence of other HPV types and HPV-negative cases tended to increase with age (p = 0.1). The prevalence of HPV types included in the nonavalent vaccine was stable around 90% until the age of 75 years and then dropped to 63%. Conclusion. In the absence of waning immunity, the nonavalent HPV vaccine would be predicted to reduce cervical cancer burden in Denmark across a broader age-range compared with the reduced type-spectrum vaccines.

AB - Introduction. The prevalence of human papillomavirus (HPV)16/18 in cervical cancer may decrease with age. This study aimed to describe the HPV genotype distribution in Danish women aged 55 years or older with cervical cancer. Material and methods. In this cross-sectional study we identified 153 cases of cervical cancer diagnosed at Aarhus University Hospital, Denmark (1990-2012) and Copenhagen University Hospital Herlev, Denmark (2007-2012). All women had surgery to treat the disease. HPV genotyping was performed on cervical cancer tissue using the INNO LiPA HPV genotyping extra (Fujirebio, Belgium) at the Department of Pathology, Aarhus University Hospital, Denmark. The main outcome was to estimate the age-specific prevalence of high-risk HPV genotypes included in the bivalent, the quadrivalent, and the nonavalent vaccine. Results. Of 121 cases of cervical cancer included in this study, 113 were HPV-positive (93.4%). Although HPV16 and 18 were the most common genotypes overall, the prevalence of HPV16/18 decreased significantly from 78.1% in women aged 55-59 years to 45.5% in women aged 75 or older (p <0.001), whereas the prevalence of other HPV types and HPV-negative cases tended to increase with age (p = 0.1). The prevalence of HPV types included in the nonavalent vaccine was stable around 90% until the age of 75 years and then dropped to 63%. Conclusion. In the absence of waning immunity, the nonavalent HPV vaccine would be predicted to reduce cervical cancer burden in Denmark across a broader age-range compared with the reduced type-spectrum vaccines.

KW - Cervical cancer

KW - genotypes

KW - human papillomavirus

KW - human papillomavirus vaccine

KW - older women

UR - http://www.scopus.com/inward/record.url?scp=84943583890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943583890&partnerID=8YFLogxK

U2 - 10.1111/aogs.12731

DO - 10.1111/aogs.12731

M3 - Article

VL - 94

SP - 1262

EP - 1268

JO - Acta Obstetricia et Gynecologica Scandinavica

JF - Acta Obstetricia et Gynecologica Scandinavica

SN - 0001-6349

IS - 11

ER -